Prognostic Role of Circular RNAs Expression in Bladder Carcinoma: A Meta-Analysis.

Circular RNAs (circRNAs), a type of noncoding RNA, are associated with the occurrence and development of cancers. In recent years, their potential as biomarkers for bladder cancer (BC) has attracted increased attention. To reveal the value of circRNAs in the prognosis of BC. Relevant studies were collected to extract the clinicopathological data and overall survival (OS) of patients with BC. We then evaluated their tumor-related clinicopathological indicators using pooled odds ratio (OR) and 95% confidence interval (CI). Hazard ratio (HR) and 95% CI were used to estimate the OS of BC patients who expressed abnormal circRNAs. The results indicate that seven circRNAs (circMYLK, circASXL1, hsa_circ_0000144, circ-VANGL1, circGprc5a, circZFR, and circ-cTFRC) whose expression was upregulated in tumor tissues, are associated with poor clinicopathological features (tumor/node/metastasis [TNM] stage: OR = 4.86, 95% CI: 2.53-9.34; histological grade: OR = 3.71, 95% CI: 2.37-5.79; lymph node metastasis: OR = 3.23; 95% CI: 2.15-4.88; recurrence: OR = 5.33; 95% CI: 2.27-12.52) and poor prognoses (OS: HR = 1.69; 95% CI: 1.17-2.44). We also found that seven circRNAs (circMTO1, circ-ITCH, circUBXN7, circFNDC3B, circ-ZKSCAN1, circPICALM, and circACVR2A) that were downregulated in tumors were associated with better clinicopathological indicators (TNM stage: OR = 0.23, 95% CI: 0.14-0.38; histological grade: OR = 0.21, 95% CI: 0.13-0.33; lymph node metastasis: OR = 0.26; 95% CI: 0.15-0.47) and better prognoses (OS: HR = 0.42; 95% CI: 0.30-0.58). Our results suggest that certain circRNAs are related to the clinicopathological characteristics and prognosis of BC patients, and may potentially be used as biomarkers.